EUVIMEDOpdag EUVIMED
Crossref

Increased Serum Levels of LDHA and TPI1 in Patients With Polycystic Ovary Syndrome

Wenjing Wang iD, Tizhen Yan, Manna Sun, Yueliang Li, Jiwu Lou

PROTEOMICS – Clinical Applications · 2026

DOI: 10.1002/prca.70032 ↗

At a glance

Journal article in PROTEOMICS – Clinical Applications, 2026. Written by Wenjing Wang and 4 co-authors. Institution: Prenatal Diagnostic Center, Dongguan Maternal and Children Health Hospital, Dongguan, Guangdong, People's Republic of China. Major MEDLINE topics: Polycystic Ovary Syndrome, Triose-Phosphate Isomerase, L-Lactate Dehydrogenase. Cited 2 times so far (Crossref); 32 references. Funded by: Basic and Applied Basic Research Program of Guangdong Province, Key Social Development Program of Dongguan City.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Polycystic ovary syndrome (PCOS) is a metabolic disorder affecting women of reproductive age, and its etiology remains unclear. Therefore, it is crucial to identify biomarkers of the metabolic disturbances in PCOS.

Methods

A total of eight clinical PCOS samples and control group samples were analyzed using data‐independent acquisition (DIA) proteomics. Clinical data were used to identify protein biomarkers, and enzyme‐linked immunosorbent assay (ELISA) validation was performed on 27 PCOS and 23 control samples.

Results

In the PCOS samples, a total of 114 differentially expressed proteins were identified, with 37 upregulated and 77 downregulated. Further biofunctional analysis using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways revealed two differentially expressed proteins, lactate dehydrogenase A (LDHA) and triosephosphate isomerase 1 (TPI1), both of which were significantly upregulated in clinical PCOS samples. LDHA and TPI1 are involved in the glycolysis/gluconeogenesis metabolic pathway. Finally, ELISA was used to validate the high expression of LDHA and TPI1 in PCOS patients.

Conclusion

DIA proteomics effectively identifies PCOS biomarkers. LDHA and TPI1 may serve as diagnostic biomarkers and could exert effects through glycolytic pathways.

Subjects

MeSH terms (MEDLINE)

Polycystic Ovary SyndromeTriose-Phosphate IsomeraseL-Lactate DehydrogenaseHumansFemaleAdultBiomarkersLactate Dehydrogenase 5ProteomicsYoung AdultCase-Control Studies

Author keywords

glucose metabolismmolecular markerspolycystic ovary syndromeproteomics

Substances

Triose-Phosphate IsomeraseBiomarkersL-Lactate DehydrogenaseLactate Dehydrogenase 5LDHA protein, human

Authors and institutions

  • Prenatal Diagnostic Center, Dongguan Maternal and Children Health Hospital, Dongguan, Guangdong, People's Republic of China.
  • Department of Obstetrics & Gynecolog, Dongguan Maternal and Children Hospital, Dongguan, People's Republic of China.

ORCID profiles: Wenjing Wang

Funding

  • Basic and Applied Basic Research Program of Guangdong Province
  • Key Social Development Program of Dongguan City

Cite

APA

Wang, W., Yan, T., Sun, M., Li, Y., & Lou, J. (2026). Increased Serum Levels of LDHA and TPI1 in Patients With Polycystic Ovary Syndrome. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70032

Vancouver

Wang W, Yan T, Sun M, Li Y, Lou J. Increased Serum Levels of LDHA and TPI1 in Patients With Polycystic Ovary Syndrome. PROTEOMICS – Clinical Applications. 2026. doi:10.1002/prca.70032

BibTeX
@article{Wang2026,
  author = {Wang, Wenjing and Yan, Tizhen and Sun, Manna and Li, Yueliang and Lou, Jiwu},
  title = {Increased Serum Levels of LDHA and TPI1 in Patients With Polycystic Ovary Syndrome},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2026},
  doi = {10.1002/prca.70032}
}
Start for free →